Have a personal or library account? Click to login
Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer – institution experience with literature review Cover

Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer – institution experience with literature review

Open Access
|Dec 2021

Figures & Tables

Figure 1

Kaplan-Meier comparing patients identified with or without residual disease following second surgery.
Kaplan-Meier comparing patients identified with or without residual disease following second surgery.

Figure 2

Kaplan-Meier comparing patients identified with or without residual disease in liver and positive lymph nodes following second surgery. (A) Residual disease in liver, (B) Positive Lymph Nodes), (C) Residual disease in liver and positive lymph nodes.
Kaplan-Meier comparing patients identified with or without residual disease in liver and positive lymph nodes following second surgery. (A) Residual disease in liver, (B) Positive Lymph Nodes), (C) Residual disease in liver and positive lymph nodes.

Figure 3

Kaplan-Meier comparing patients identified with II and III stage disease following second surgery.
Kaplan-Meier comparing patients identified with II and III stage disease following second surgery.

Output of the multivariate Cox regression model

Estimates
VariableBetaStandard errorp-valueHazard ratio exp(Beta)95% confidence interval
RD in liver or/and positive lymph nodes (Yes/No)1.2530.7920.1140.2860.0611.349
Stage (II/III)1.7161.1300.1290.1800.0201.648
Age0.0270.0330.4151.0280.9621.097
Days between the two operations0.0010.0020.7170.9990.9961.003

Characteristics of patients with incidentally detected gallbladder cancer at the time of second surgery and survival characteristics at 1, 3, and 5 years after the intervention

CharacteristicsAt second surgery (n = 22)Time after secondary intervention
1 year (n = 17) n (%)3 year (n = 12) n (%)5 year (n = 9) n (%)
Age at secondary intervention (years)
     < 657 (31.8)6 (35.3)3 (25.0)2 (22.2)
     65–7510 (45.5)7 (42.2)6 (50.0)5 (55.6)
     > 755 (22.7)4 (23.5)3 (50.0)2 (22.2)
Time between the two interventions (days)
     < 6013 (59.1)11 (64.7)8 (66.7)6 (66.7)
     > 609 (40.9)6 (35.3)4 (33.3)3 (33.3)
Residual disease in liver
     No15 (68.2)13 (76.5)12 (100.0)9 (100.0)
     Yes7 (31.8)4 (23.5)//
Positive lymph nodes
     No9 (40.9)7 (41.2)6 (50.0)6 (66.7)
     Yes9 (40.9)6 (35.3)3 (25.0)2 (22.2)
     No data4 (18.2)4 (23.5)3 (25.0)1 (11.1)
Secondary surgery
     4b,5 segmentectomy + lymphadenectomy9 (41.0)9 (53.0)6 (50.0)4 (44.4)
     4b,5 segmentectomy + CBD resection9 (41.0)7 (41.2)6 (50.0)5 (55.6)
     ALPPS + CBD resection1 (4.5)///
     Extended right hepatectomy + Whipple procedure1 (4.5)1 (5.8)//
     4b,5,6 segmentectomy + resection of CBD,1 (4.5)///
     stomach and proximal duodenum
     CBD resection1 (4.5)///
Stage
     Stage II9 (40.9)9 (52.9)7 (58.3)6 (66.7)
     Stage III13 (59.1)8 (47.1)5 (41.7)3 (33.3)
Complications (Clavien-Dindo scale)
     None15 (68.2)14 (82.4)9 (75.0)7 (77.8)
     Grade I1 (4.5)1 (5.9)1 (4.5)1 (11.1)
     Grade II4 (18.3)2 (11.8)2 (16.7)1 (11.1)
     Grade IVb1 (4.5)///
     Grade V1 (4.5)///
DOI: https://doi.org/10.2478/raon-2021-0048 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 208 - 215
Submitted on: Aug 25, 2021
Accepted on: Oct 27, 2021
Published on: Dec 22, 2021
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2021 Mihajlo Đokic, Urban Stupan, Sabina Licen, Blaz Trotovsek, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.